Artificial cells for in vivo biomedical applications through red blood cell biomimicry.

Autor: Waeterschoot J; Department of Biosystems - MeBioS, KU Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium. jorik.waeterschoot@kuleuven.be., Gosselé W; Department of Biosystems - MeBioS, KU Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium., Lemež Š; Department of Biosystems - MeBioS, KU Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium., Casadevall I Solvas X; Department of Biosystems - MeBioS, KU Leuven, Willem de Croylaan 42, 3001, Leuven, Belgium. xevi.casadevall@kuleuven.be.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Mar 20; Vol. 15 (1), pp. 2504. Date of Electronic Publication: 2024 Mar 20.
DOI: 10.1038/s41467-024-46732-8
Abstrakt: Recent research in artificial cell production holds promise for the development of delivery agents with therapeutic effects akin to real cells. To succeed in these applications, these systems need to survive the circulatory conditions. In this review we present strategies that, inspired by the endurance of red blood cells, have enhanced the viability of large, cell-like vehicles for in vivo therapeutic use, particularly focusing on giant unilamellar vesicles. Insights from red blood cells can guide modifications that could transform these platforms into advanced drug delivery vehicles, showcasing biomimicry's potential in shaping the future of therapeutic applications.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: